Immunovant
IMVT
226 hedge funds and large institutions have $4.25B invested in Immunovant in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 74 increasing their positions, 79 reducing their positions, and 24 closing their positions.
464% more call options, than puts
Call options by funds: $87.6M | Put options by funds: $15.5M
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
55% more capital invested
Capital invested by funds: $2.75B → $4.25B (+$1.5B)
5% more funds holding
Funds holding: 215 → 226 (+11)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.57% less ownership
Funds ownership: 54.34% → 53.77% (-0.57%)
6% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$130M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$37.8M |
| 4 |
Morgan Stanley
New York
|
+$20M |
| 5 |
BlackRock
New York
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$66.6M |
| 2 |
AC
Armistice Capital
New York
|
-$55.7M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$42.4M |
| 4 |
AGM
Alpine Global Management
New York
|
-$38.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.2M |
IMVT Hedge Fund Activity: Q2 2026 in Review
226 of the 8,296 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2026, worth a combined $4.25B — up 55% from $2.75B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IMVT positions and 24 closed out — a net gain of 15 holders — while 74 added to existing stakes and 79 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $130M. The largest seller was Deep Track Capital, cutting an estimated $66.6M.
- 226 institutional investors held Immunovant (IMVT) as of Q2 2026, up from 215 in Q1 2026.
- Funds reported $4.25B of Immunovant stock for Q2 2026, up 55% quarter-over-quarter.
- 39 funds opened new Immunovant positions in Q2 2026 and 24 closed out, a net change of +15 holders.
- The largest Immunovant buyer in Q2 2026 was Farallon Capital Management, an estimated $130M added.
- The largest Immunovant seller in Q2 2026 was Deep Track Capital, an estimated $66.6M sold.
Based on aggregated 13F filings for Q2 2026.